WO2009115634A1 - Combinaciones sinérgicas de 5'-metiltioadenosina - Google Patents
Combinaciones sinérgicas de 5'-metiltioadenosina Download PDFInfo
- Publication number
- WO2009115634A1 WO2009115634A1 PCT/ES2009/070067 ES2009070067W WO2009115634A1 WO 2009115634 A1 WO2009115634 A1 WO 2009115634A1 ES 2009070067 W ES2009070067 W ES 2009070067W WO 2009115634 A1 WO2009115634 A1 WO 2009115634A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mta
- multiple sclerosis
- treatment
- pharmaceutically acceptable
- combination
- Prior art date
Links
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 title claims abstract description 104
- 230000002195 synergetic effect Effects 0.000 title description 7
- 108010072051 Glatiramer Acetate Proteins 0.000 claims abstract description 115
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims abstract description 110
- 229960003776 glatiramer acetate Drugs 0.000 claims abstract description 109
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 77
- 238000011282 treatment Methods 0.000 claims abstract description 48
- 230000002265 prevention Effects 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims description 47
- 239000000651 prodrug Substances 0.000 claims description 41
- 229940002612 prodrug Drugs 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 7
- 229960001156 mitoxantrone Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 14
- 201000002491 encephalomyelitis Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- -1 adenosine nucleoside Chemical class 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 229940038717 copaxone Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229960001570 ademetionine Drugs 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 229960001388 interferon-beta Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960005027 natalizumab Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005137 succinic acid Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- SSNHGLKFJISNTR-DYSNNVSPSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-DYSNNVSPSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 241000478345 Afer Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000003835 adenosine derivatives Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229950009925 atacicept Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- VERAMNDAEAQRGS-UHFFFAOYSA-N butane-1,4-disulfonic acid Chemical compound OS(=O)(=O)CCCCS(O)(=O)=O VERAMNDAEAQRGS-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- LEUIUWYZAHKPSE-UHFFFAOYSA-L disodium;butane-1,4-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCCCS([O-])(=O)=O LEUIUWYZAHKPSE-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000028756 lack of coordination Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
- 229960004577 laquinimod Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to combinations of 5'-me t i 11 ioadenos ina and glatiramer acetate, and their use in the prevention and / or treatment of multiple sclerosis.
- the present invention relates to a product comprising 5'-methylthioadenosine and glatiramer acetate as a combined preparation for simultaneous use, separately or sequentially, for the prevention and / or treatment of multiple sclerosis.
- MS Multiple sclerosis
- Be t aser ón® / Be t afer ón® (interferon beta-Ib)
- Interferon beta-la (Serono, Geneva, Switzerland)]; glatiramer acetate (GA) (Copaxone®; Teva, Nordani, Israel); mitoxantrone (Novantrone®; Serono, Geneva, Switzerland); and natalizumab (Tysabri®; Biogen poufon®; Interferon beta-Ib is effective in relapsing remitting multiple sclerosis.
- G glatiramer acetate
- mitoxantrone Novantrone®; Serono, Geneva, Switzerland
- natalizumab (Tysabri®; Biogen personal) [Jacobs et al. Ann Neurol (1996), 39: 285-294; IFN ⁇ Multiple Sclerosis Study Group.
- Interferon beta-Ib is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology (1993), 43: 655-661
- Interferons-beta and GA act as first-line agents and have been used routinely for about a decade. These approved anti-MS drugs have the disadvantage that they need to be administered subcutaneously (interferon-beta or GA), intramuscularly (interferon beta-la) or intravenously
- combination therapies of class 1 include two (or more drugs) that are considered independent of each other and address different aspects of the underlying mechanisms of the disease [ Toews et al. Proc Am Thorac Soc (2005), 2: 282-289].
- Glatiramer acetate also known as Copolymer 1, Cop 1, copaxone or GA, is a synthetic non-pathogenic random copolymer composed of the four amino acids: L-GIu, L-Lys, L-AIa and L-Tyr.
- GA may represent the ideal candidate to accompany other agents to achieve complementary and potentially synergistic therapeutic effects [Costello et al. Curr Op Neurology (2007), 20: 281-285].
- Boggild [Boggild. J Neurol (2006), 253 (Suppl 6): VI / 45-VI / 51] and Ramtahal et al [Ramtahal et al. J Neurol (2006), 253: 1160-1164] used mitoxantrone as induction therapy followed by maintenance therapy with GA in a series of non-randomized uncontrolled observational cases, and observed a 90% reduction in relapse rate among patients.
- WO2005 / 009333 discloses that heteropolymers or peptides related to Copolymer 1 (GA) in combination with other immunosuppressive drugs induce an unexpected synergistic effect and, thus, improve the efficacy of current immunosuppressive patterns.
- GA therapy has some drawbacks that derive from its required fixed dose and the fact that the response is very sensitive to a specific administration schedule, requiring daily doses to achieve its effectiveness.
- individual immune responses after immunization with GA differ between individuals depending on the genetic basis or other immunological factors, leading to a range of different degrees of responders.
- the current effectiveness of GA in preventing new recurrences in MS is not more than 25%. This limited efficacy prevents its widespread use in several countries and is often prescribed to patients with a mild illness; Often, patients with a more serious illness are not treated with GA.
- GA is only approved today for the treatment of MS sender-recurring
- MTA 5'methylthioadenosine
- SAM S-adenosylmethionine
- MTA is capable of preventing acute Experimental Autoimmune Encephalomyelitis (EAE) and improves Chronic Recidivism EAE (RR-EAE), two different models of MS, by modulating T cell activation, decreasing inflammation and demyelination in the central nervous system [Moreno et al. Ann Neurol (2006) Sep, 60 (3): 323-334].
- EAE Experimental Autoimmune Encephalomyelitis
- RR-EAE Chronic Recidivism EAE
- MTA is a suitable drug for oral formulations due to its small size and hydrophilic character.
- EP 352609 describes the use of adenosine derivatives, in particular MTA, in the preparation of pharmaceutical compositions that possess immunostimulatory activity.
- WO2006 / 097547 describes the use of MTA in the prevention and / or treatment of autoimmune diseases, such as MS and in the prevention and / or treatment of transplant rejection.
- the MTA specifically modulates immune responses dependent on the activation of CD4 + cells through the chemical modulation of signaling mechanisms.
- GA has demonstrated a competitive activity for the binding of the specific T-cell receptor for Myelin Basic Protein (PBM).
- PBM Myelin Basic Protein
- GA can be considered as a vaccine for inducing immune tolerance against brain auto-antigens. It has been observed that GA therapy induces a shift towards Th2 responses and activation of regulatory T cells that suppress the immune response. Due to its vaccine-like mechanism of action, in order to be effective, GA needs to induce an immune response against CD4 +-mediated GA. Since MTA suppresses the activation of CD4 +, which is necessary for the generation of GA-specific T cell responses, one could expect that the combination of MTA and GA could be neutral or even harmful.
- PBM Myelin Basic Protein
- the combination of MTA and GA has several advantages as it can overcome the individual and limited effectiveness of GA.
- the combination of MTA and GA also allows a flexible dosage schedule, which will increase the opportunities to have a good control of the disease and the expansion of its indication for a wider group of patients, allowing an individualized therapy through adjustment. of dosage guidelines to the specific needs of a particular patient.
- the combination therapy of MTA and GA is clearly beneficial in terms of improving the patient's quality of life by decreasing the amount of injections to be administered.
- the present invention is refers to a combination comprising (A) MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and (B) GA.
- the invention relates to a product comprising (A) MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and (B) GA, as a combined preparation.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising said combination comprising (A) MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and (B) GA.
- the present invention relates to a product comprising, separately, (A) MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and (B) GA, as a combined preparation for simultaneous use, separately , or sequential, in the prevention and / or treatment of multiple sclerosis.
- the combination, pharmaceutical composition or product referred to above are particularly useful in the prevention and / or treatment of MS, in particular, in a recurrent form of MS, more particularly, in a remitting-r ecurring form of MS, even more particularly , in a remitting-recurring form of MS with the presence of one or more outbreaks after being treated only with GA for at least 6 months.
- Figure 1 is a graph showing the chronological score of the disease severity of
- EAE developed by C57 / bl6 mice treated daily with placebo, MTA, GA or MTA + GA.
- MTA and / or its pharmaceutically acceptable salts and / or prodrugs refers to MTA alone, as well as a pharmaceutically acceptable salt of MTA alone, as a prodrug of MTA alone, or combinations thereof.
- terapéuticaally effective amount means an amount of a compound or combination of compounds that treats a disease; improves, attenuates or eliminates one or more symptoms of a specific disease; or prevents or delays the appearance of one or more symptoms of a disease.
- pharmaceutically acceptable means that a compound or combination of compounds is compatible with the other ingredients of a formulation and not harmful to the patient.
- pharmaceutically acceptable salts refers to any MTA salt that can be used in the manufacture of a medicament.
- the nature of salt is not critical as long as it is not toxic and pharmaceutically acceptable.
- pharmaceutically acceptable salts of MTA are acid addition salts, which can be obtained from acids, organic or inorganic, by conventional methods well known to those skilled in the art by reacting the appropriate acid with the MTA in the Amount is adequate tequiomét rica.
- MTA hydrochloride can be used in injectable formulations; In oral formulations, MTA hydrochloride, MTA sulfate, MTA citrate, MTA ascorbate, MTA 1,4-butanedisulfonate (gastro-resistant tablets), MTA p-toluenesulfonate, etc. can be used.
- therapeutically acceptable salts of MTA are administered in pharmaceutically acceptable concentrations.
- MTA addition salts can be converted by treatment with a suitable base in the form of free base.
- prodrug includes any compound derived from MTA which, when administered to a subject is capable of providing, directly or indirectly, MTA in said subject.
- MTA prodrugs include their acylated derivatives (eg, acetylated or other), their esters (eg, their pyridine-esters or others), etc. (WO98 / 16184).
- said MTA derivative is a compound that increases the bioavailability of MTA when it is administered to a subject or that enhances the release of MTA in a biological compartment.
- the nature of said derivative is not critical as long as it can be administered to a subject and provides MTA in a biological compartment of that subject.
- the preparation of said prodrug can be carried out by conventional methods known to those skilled in the art.
- prevention refers to preventing the occurrence or recurrence of a disease, disorder or condition to which the term is applied, or of one or more symptoms associated with a disease, disorder, from occurring, or, alternatively. or condition
- prevention refers to the act of prevention, which has already been defined above.
- treat refers to reversing, alleviating or inhibiting the progress of the disorder or condition to which said term applies, or one or more symptoms of said disorders or condition.
- treatment refers to the act of treating, which has already been defined above.
- subject means animals, particularly mammals, such as dogs, cats, cows, horses, sheep, geese and humans. Particularly preferred patients are mammals, including humans of both sexes.
- a sclerosis is a progressive hardening, or hardening, and refers especially to the hardening of a tissue due to inflammation and the increased formation of connective tissue and in diseases of the interstitial substance.
- the term "sclerosis” is mainly used for said hardening of the nervous system due to the deposition of fibrotic tissue, or for Point out the hardening of the blood vessels.
- MS Multiple sclerosis
- RRMS relapsing-remitting multiple sclerosis
- SPMS progressive secondary multiple sclerosis
- PPMS progressive primary multiple sclerosis
- PRMS progressive-recurrent multiple sclerosis
- Progressive chronic multiple sclerosis is a term used h ab i t u a 1 me n t e to refer collectively to SPMS, PPMS and PRMS.
- the recurring forms of MS are SPMS with overlapping recurrences, RRMS and
- MTA (5'-methylthioadenosine) [CAS Registry Number: 2457-80-9] has the following structural formula:
- MTA is a commercial product that can be provided by the Sigma company. Alternatively, this compound can be obtained by known procedures, for example, from S-adenosyl methionine.
- Copaxone® is the trade name of a formulation containing glatiramer acetate (GA) as the active substance. GA is approved to reduce the frequency of recurrences in relapsing-remitting multiple sclerosis (RRMS). GA is a synthetic copolymer composed of four natural amino acids, specifically, L-glutamic acid, L-alanine, L-tyrosine and L-lysine, with an average mole fraction in Copaxone® of 0.141, 0.427, 0.095 and 0.338, respectively. In Copaxone®, the average molecular weight of GA is 4,700-11,000 Daltons.
- GA is designated as acetate (salt) of L-glutamic acid, polymer of L-alanine, L-lysine and L-tyrosine; Its CAS Registry number is 147245-92-9, and its structural formula is:
- the present invention relates to a combination, hereinafter combination of the invention, comprising:
- Said combination of the invention is particularly useful for preventing and / or treating multiple sclerosis (MS), in any of its forms.
- the "combination of the invention” constitutes a combined composition in which its components can be arranged according to different alternative presentations.
- the combination of the invention is presented as a product or kit comprising the components [(A) and (B)] of the combination in one, two or more packages, and, optionally, other components or elements ( eg, vials, syringes, etc.); said product or kit may be, among others, a single package composition ("one pack composition") or a composition in two packages ("two pack composition”).
- the combination of the invention is suitable as a combined preparation for simultaneous use, separately and / or sequentially, in the prevention and / or treatment of multiple sclerosis.
- the invention relates to a product comprising: (A) 5'-methylthioadenosine (MTA) and / or its pharmaceutically acceptable salts and / or prodrugs, and (B) glatiramer acetate (GA) , as a combined preparation.
- MTA 5'-methylthioadenosine
- G glatiramer acetate
- the combination of the invention may additionally comprise one or more additional compounds useful in the treatment of MS, such as an interferon-beta (eg, interferon beta-la, interferon beta-Ib, etc.), mitoxantrone , natalizumab, fingolimod, laquinimod, rituximab, daclizumab, frampidine, sativex, alentuzumab, fumaric acid, ter if lunomide, cladibrine, mycophenolate mofetil, ibudilast, atacicept, etc.
- an interferon-beta eg, interferon beta-la, interferon beta-Ib, etc.
- mitoxantrone e.g, mitoxantrone
- natalizumab fetal
- fingolimod fetal
- laquinimod rituximab
- daclizumab daclizumab
- frampidine
- the combination of the invention is particularly suitable for the prevention and / or treatment of MS, in any of its forms, said combination of the invention can be used as a medicament.
- the invention relates to the use of said combination of the invention, in the preparation of a medicament for preventing and / or treating MS in a subject.
- the present invention provides a combination of the invention for use in the prevention and / or treatment of MS in a subject, that is, the present invention provides a product comprising, separately, (A) MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and (B) GA, as a combined preparation for simultaneous, separate, or sequential use, in the prevention and / or treatment of multiple sclerosis.
- the present invention provides a method for prevention and / or treatment of MS comprising administration to a subject in need of said prevention and / or treatment of a therapeutically effective amount of a combination of the invention.
- the combination of the invention is used in the prevention and / or treatment of any form of MS, ie, benign multiple sclerosis, RRMS, SPMS, PPMS, and PRMS.
- the combination of the invention is useful in the prevention and / or treatment of repeated forms of MS, that is, RRMS and PRMS.
- the combination of the invention is useful in the prevention and / or treatment of relapsing-remitting forms of MS, in particular RRMS.
- the combination of the invention is useful in the prevention and / or treatment of subjects with RRMS, with the presence of one or more outbreaks, after being treated only with GA for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months.
- the combination of the invention is useful in the prevention and / or treatment of subjects suffering from MS and who have completed a mitoxantrone therapy with GA.
- the amount of MTA and / or its pharmaceutically acceptable salts and / or prodrugs, when taken alone, as well as the amount of GA when taken alone, is usually effective in relieving symptoms of any form of MS (i.e., the treatments are partially effective).
- the amount of MTA and / or its pharmaceutically acceptable salts and / or prodrugs, when taken alone, or the amount of GA when taken alone may not be effective in relieving symptoms of any of the forms of MS (that is, individual treatments are not effective but combined if they are).
- the dose to be administered of MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and GA depends on the individual case and, as usual, must be adapted to the conditions of the individual case for optimum effect. Therefore, it depends naturally on the frequency of administration and the potency and duration of action of the compounds used in each case for therapy or prophylaxis, but also on the nature and severity of the disease and symptoms, and of sex, age, weight, joint medication (co-medication) and the individual sensitivity of the subject to be treated and whether the therapy is acute or prophylactic.
- the therapeutically effective amount of MTA and / or its pharmaceutically acceptable salts and / or prodrugs may be in the range of 0.01 mg to 50 g per day; from 0.02 mg to 40 g per day; from 0.05 mg to 30 g per day; from 0.1 mg to 20 g per day; from 0.2 mg to 10 g per day; 0.5 mg to 5 g per day; from 1 mg to 3 g per day; from 2 mg to 2 g per day; from 5 mg to 1.5 g per day; from 10 mg to 1 g per day; or from 10 mg to 500 mg per day.
- the therapeutically effective amount of GA may be in the range of 50 to 150 mg / day; 60 to 140 mg / day; from 70 to 130 mg / day; from 80 to 120 mg / day; from 90 to 110 mg / day; or is 100 mg / day. Also, in another particular embodiment, the amount of GA may be in the range of 10 to 80 mg / day; from 12 to 70 mg / day; from 14 to 60 mg / day; from 16 to 50 mg / day; from 18 to 40 mg / day; from 19 to 30 mg / day; or is about 20 mg / day.
- the administration of GA is based on a daily schedule, alternately in a twice-daily schedule daily administering in each guideline half of the daily amount to administer.
- the periodic administration of GA is performed once every 3 to 11 days; once every 5 to 9 days; once every 7 days; or once every 24 hours.
- the MTA and / or its pharmaceutically acceptable salts and / or prodrugs can be administered once every 6 to 24 hours; once every 7 to 22 hours; once every 8 to 20 hours; once every 9 to 18 hours; once every 10 to 16 hours; once every 11 to 14 hours; or once every 12 hours.
- MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and GA can be administered together, either in separate pharmaceutical compositions or as part of the same unit dosage form.
- the MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and the GA can be administered separately, but as part of the same therapeutic regimen.
- the two components, if administered separately, do not necessarily have to be administered essentially at the same time, although it can be done if desired.
- MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and GA can be administered as separate doses or dosage forms, but at the same time.
- separate administration of the MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and of the GA can be performed at different times and in any order.
- the administration of GA precedes its administration to the MTA and / or its pharmaceutically acceptable salts and / or prodrugs.
- the administration of the MTA and / or its Pharmaceutically acceptable salts and / or prodrugs substantially precedes the administration of GA.
- GA and MTA and / or their pharmaceutically acceptable salts and / or prodrugs can be administered for a period of at least 4 days.
- the period of time may be from 5 days to 5 years; from 10 days to 3 years; from 2 weeks to 1 year; from 1 month to 6 months; or from 3 months to 4 months.
- the GA and the MTA and / or its pharmaceutically acceptable salts can be administered and / or can be administered during the lifetime of the subject.
- MTA and / or its pharmaceutically acceptable salts and / or prodrugs, as well as GA can be administered, independently of one another, by any appropriate route, for example, by oral, nasal, pulmonary, parenteral, intravenous, intraarticular, transdermal route , intradermal, subcutaneous, topical, intramuscular, rectal, intrathecal, intraocular, buccal or by tube.
- the route of administration of the MTA and / or its pharmaceutically acceptable salts and / or prodrugs is the oral or probe route.
- the preferred route of administration for GA is the subcutaneous or oral route.
- One skilled in the art will recognize the dose at the highest end of the range that may be necessary for oral administration.
- GA can be administered subcutaneously, intr ape rit one to 1, intravenously, intramuscularly, intraocularly or orally, and the administration of MTA and / or its pharmaceutically acceptable salts and / or prodrugs, may be oral.
- the administration of the GA can be subcutaneous and the administration of the MTA and / or its salts Pharmaceutically acceptable and / or prodrugs, can be oral.
- the present invention relates to a pharmaceutical composition, hereinafter pharmaceutical composition of the invention, comprising a therapeutically effective amount of a combination of the invention, comprising (A) MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and (B) GA, and a pharmaceutically acceptable excipient.
- the amount of GA, when taken alone, as well as the amount of MTA and / or its pharmaceutically acceptable salts and / or prodrugs, when taken alone, in the pharmaceutical composition of the invention is effective in relieving the symptoms of MS (that is, individual treatments are partially effective).
- the amount of GA, when taken alone, or the amount of MTA and / or its pharmaceutically acceptable salts and / or prodrugs, when taken alone may not be effective in relieving the symptoms of MS in any of its forms. (that is, individual treatments are not effective but combined if they are).
- the amount of GA in the pharmaceutical composition of the invention may coincide with the therapeutically effective daily dose and be in the range of 10 to 80 mg, 12 to 70 mg, 14 to 60 mg, 16 to 50 mg, of 18 to 40 mg, 19 to 30 mg, or about 20 mg.
- the amount of GA in the pharmaceutical composition of the invention may be in the range of 50 to 150 mg, 60 to 140 mg, 70 to 130 mg, 80 to 120 mg, 90 at 110 mg, or is about 100 mg.
- the amount of MTA and / or its pharmaceutically acceptable salts and / or prodrugs, in the pharmaceutical composition of the invention may be in the range of 0.01 mg to 50 g, 0.02 mg to 40 g, 0.05 mg to 30 g, 0 , 1 mg to 20 g, 0.2 mg to 10 g, ⁇ , 5 mg to 5 g, l mg to 3 g, 2 mg to 2 g, 5 mg to 1.5 g, 10 mg to 1 g, from 10 mg to 500 mg.
- the pharmaceutical composition of the invention is intended for administration subcutaneously, intraperitoneally, intravenously, intramuscularly or intraocularly.
- the invention relates to a product, hereinafter product of the invention, comprising MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and GA as a combined preparation for simultaneous, separate or sequential use, in the prevention and / or treatment of MS.
- the present invention further relates to a kit, hereinafter kit of the invention, comprising a combination of separate pharmaceutical compositions, wherein at least one of said pharmaceutical compositions comprises MTA and / or its It is pharmaceutically acceptable and / or prodrugs, and at least one of said pharmaceutical compositions comprises GA.
- the kit of the invention comprises two separate pharmaceutical compositions, one of them comprising MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and the other GA.
- the kit also comprises a container for said separate pharmaceutical compositions, such as a compartmentalized bottle or a compartmentalized laminated package.
- containers include syringes, boxes, bags and the like.
- kits includes indications for the administration of the separate components.
- the way of kit is particularly advantageous when the separated components are preferably administered in different dosage forms (eg, oral and parenteral), when they are administered at different dosage intervals, or when the requesting physician wishes to adjust the dose of the individual components of the combination .
- the product of the invention or the kit of the invention are particularly suitable for the prevention and / or treatment of multiple sclerosis.
- the product of the invention or the kit of the invention is used in the prevention and / or treatment of any form of MS, e.g., benign multiple sclerosis, RRMS, SPMS, PPMS, or PRMS.
- the product of the invention or the kit of the invention is useful in the prevention and / or treatment of repeated forms of MS, that is, RRMS and PRMS.
- the product of the invention or the kit of the invention is useful in the prevention and / or treatment of relapsing-remitting forms of MS, in particular RRMS.
- the product of the invention or the kit of the invention is useful in the prevention and / or treatment of subjects with RRMS with the presence of one or more recurrences after treatment with GA only for at least 1 month. , 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months or 12 months.
- the combination of the invention, the product of the invention or the kit of the invention are useful in the prevention and / or treatment of subjects suffering from MS and who have completed a mitoxantrone therapy with GA.
- kits of the invention An example of presenting a kit of the invention is a blister.
- Blister packs are well known in the packaging industry and are widely used. for the packaging of pharmaceutical unit dosage forms (tablets, capsules, syringes, sterile powders and the like).
- the blisters generally consist of a sheet of a relatively rigid material coated with a film of a preferably transparent plastic material. During the packaging process holes or cavities are formed in the plastic film. The voids have the size and shape of the tablets or capsules to be packaged. Alternatively, the blister holes or cavities are conveniently manufactured to contain the fluid injectable medicament or the sterile powder to be reconstituted.
- a memory aid in the kit, for example, in the form of numbers next to the tablets, capsules, or injectable fluid, whereby the numbers correspond to the days of the specified tablet or capsule schedule that They must be ingested.
- a calendar printed on the card for example, indicating "First week, Monday, Tuesday, etc., Second Week, Monday, Tuesday," etc.
- a "daily dose” may be a single tablet, capsule or injectable fluid, or several injectable pills, capsules or fluids to be taken on a given day.
- a daily dose of MTA and / or its pharmaceutically acceptable salts and / or prodrugs may consist of several tablets or capsules, while a daily dose of GA may consist of a single injectable fluid and vice versa.
- the memory aid should reflect this and help in the proper administration of active agents.
- the present invention relates to a dispenser designed to dispense the daily doses of each component (MTA and / or its salts pharmaceutically acceptable and / or prodrugs, and GA), one at a time, in the order of its intended use.
- the dispenser is equipped with a memory aid to further facilitate compliance with the dosage schedule.
- a memory aid is a mechanical counter that indicates the number of daily doses that have been dispensed.
- a battery-powered memory microchip coupled with a liquid crystal reading device, or an audible reminder signal, for example, that reads the date of the last daily dose that has been taken and / or remember when the next dose should be taken.
- the amount of GA may coincide with the therapeutically effective daily dose and be in the range of 10 to 80 mg, 12 to 70 mg, of 14 to 60 mg, 16 to 50 mg, 18 to 40 mg, 19 to 30 mg, or about 20 mg.
- the amount of GA in the kit of the invention or in the product of the invention may be in the range of 50 to 150 mg, 60 to 140 mg, 70 to 130 mg, 80 at 120 mg, 90 to 110 mg, or about 100 mg.
- the amount of MTA and / or its pharmaceutically acceptable salts and / or prodrugs, in the same kit or product may be from 0.01 mg to 50 g, from 0.02 mg to 40 g, from 0.05 mg to 30 g, from 0.1 mg to 20 g, from 0.2 mg to 10 g, from 5, 5 mg to 5 g, from l mg at 3 g, from 2 mg to 2 g, from 5 mg to 1.5 g, from 10 mg to 1 g, from 10 mg to 500 mg.
- MTA and / or its pharmaceutically acceptable salts and / or prodrugs, and GA can be administered to a subject orally, rectally, parenterally (for example, intravenously, intramuscularly, subcutaneously, etc.), intracisternal, intravaginal, intraperitoneal, intravesical, local (for example, by means of powders, ointments, drops, etc.), or as a mouth or nasal spray.
- compositions of the invention suitable for parenteral injection, include sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, physiologically acceptable, or may comprise sterile powders for reconstitution into sterile injectable solutions or dispersions.
- suitable carriers, diluents, solvents or aqueous or non-aqueous vehicles include water, ethanol, polyols (polypropylene tongue 1, polyethylene glycol, glycerol and the like), suitable mixtures thereof, triglycerides, including vegetable oils, such as olive oil, or injectable organic esters, such as ethyl oleate.
- compositions may also include pharmaceutically acceptable adjuvants or carriers known to those skilled in the art.
- adjuvants include Freund's complete adjuvant and Freund's incomplete adjuvant.
- the pharmaceutical compositions provided by this invention may also comprise wetting agents, emulsifying and suspending agents, sweeteners, flavorings, colorants, perfuming agents and preservatives.
- the prevention of contamination by microorganisms of the formulations can be accomplished by the addition of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
- isotonic agents for example, sugars, sodium chloride, and the like.
- Prolonged absorption of injectable pharmaceutical formulations can be caused by using agents capable of delaying absorption, for example, aluminum monostearate and / or gelatin.
- GA can be formulated in pharmaceutical compositions with pharmaceutically acceptable carriers, such as water, saline and can be formulated in eye drops. GA can also be formulated in release systems, such as matrix systems.
- Solid dosage forms for oral administration include capsules, tablets, powders and granules.
- the active compound is mixed with at least one usual inert excipient (or carrier), such as sodium citrate or dicalcium phosphate or
- fillers or extenders such as, for example, starches, lactose, sucrose, mannitol or silicic acid;
- binders such as, for example, carboxymethyl cellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose or acacia;
- disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, algic acid, certain complex silicates, or sodium carbonate;
- solution retarders such as paraffin;
- absorption accelerators such as quaternary ammonium compounds;
- wetting agents such as, for example, cetyl alcohol or
- Solid formulations of a similar type can also be used as refills. filled, soft or hard gelatin, using excipients such as lactose or milk sugar, as well as high molecular weight polyethylene glycols, and the like.
- Solid dosage forms such as dragees, capsules and granules can be prepared with coatings or envelopes, such as enteric coatings and others known in the art. They may also contain opacifying agents and may be formulated so as to release the active principle or principles in a delayed manner. Examples of impregnation formulations (“embedding") that can be used are polymeric substances and waxes. The active substances may be in microencapsulated form, if appropriate, with one or more of the excipients mentioned above.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing and emulsifying agents, such as, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate , benzyl alcohol, benzyl benzoate, propyl tongue, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, oil of sesame seed, Miglyol®, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, sorbitan fatty acid esters, or mixtures of these substances and the like.
- the formulation may also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents and perfuming agents.
- the suspensions in addition to the active principle or principles, may contain suspending agents, such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol or sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, or tragacanth, or mixtures thereof substances, and the like.
- mice C57 / bl6 of Charles River, 6-8 were used weeks of life and 20 g of body weight, which were placed in plastic cages, and provided with granules of commercial food and water ad libitum.
- EAE Induction and Score Mice were immunized at the base of both hind legs with 100 ⁇ l of an incomplete Freund's saline and adjuvant emulsion (IFA) containing 300 ⁇ g of mouse rMOG35-55 (Sigma), at equal volumes, and supplemented with 5 mg / ml of Mycobacterium tuberculosis (strain H37Ra) (Difco). Subsequently, at 24 h and at 72 h post-immunization, 500 mg of pertussis toxin (Sigma) were administered intra-peritonally (ip).
- IFA incomplete Freund's saline and adjuvant emulsion
- EAE clinical signs of disease
- MTA 5'-Methylthioadenosine
- Glatiramer acetate was obtained from Teva Pharmaceutical Industries (Petah Tiqva, Israel) and applied by an i.p. daily of 100 ⁇ l of 0.5 mg / ml (0.1 mg / mouse / day).
- the animals were anesthetized and an intracardiac perfusion with 4% paraformaldehyde was carried out in 0.1 M phosphate buffer (pH 7.6). Brains and segments of the cervical, thoracic and lumbar spinal cord were dissected and fixed overnight. After incubation in 5% sucrose overnight at 4 0 C, the tissue was inserted into paraffin to perform histopathology and immunohistochemical studies.
- the animals were randomly assigned to daily treatment with placebo, MTA, GA or MTA + GA and were blindly evaluated.
- results obtained indicate that the joint administration of MTA and GA has a synergistic effect in suppressing brain autoimmunity in the EAE model. These results show that the combination therapy of MTA and GA produces a greater benefit for patients suffering from MS compared to current therapies in which only GA is administered.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/922,980 US8236778B2 (en) | 2008-03-19 | 2009-03-18 | Synergistic 5′-methylthioadenosine combinations |
BRPI0909189A BRPI0909189A2 (pt) | 2008-03-19 | 2009-03-18 | combinações sinergísticas de 5'-metiltioadenosina |
MX2010010094A MX2010010094A (es) | 2008-03-19 | 2009-03-18 | Combinaciones sinergicas de 5'-metiltioadenosina. |
CA2717419A CA2717419A1 (en) | 2008-03-19 | 2009-03-18 | Synergic 5'-methylthioadenosine combinations |
JP2011500244A JP2011515377A (ja) | 2008-03-19 | 2009-03-18 | 相乗的な5’−メチルチオアデノシンの組み合わせ |
AU2009227068A AU2009227068A1 (en) | 2008-03-19 | 2009-03-18 | Synergistic combinations of 5' -methylthioadenosine |
CN200980109743XA CN101977613A (zh) | 2008-03-19 | 2009-03-18 | 5′-甲基硫腺苷的协同组合物 |
EP09722096A EP2281566A1 (en) | 2008-03-19 | 2009-03-18 | Synergic 5'-methylthioadenosine combinations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200800806A ES2329327B1 (es) | 2008-03-19 | 2008-03-19 | Combinaciones sinergicas de 5'-metiltioadenosina. |
ESP200800806 | 2008-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009115634A1 true WO2009115634A1 (es) | 2009-09-24 |
Family
ID=40785496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2009/070067 WO2009115634A1 (es) | 2008-03-19 | 2009-03-18 | Combinaciones sinérgicas de 5'-metiltioadenosina |
Country Status (11)
Country | Link |
---|---|
US (1) | US8236778B2 (es) |
EP (1) | EP2281566A1 (es) |
JP (1) | JP2011515377A (es) |
CN (1) | CN101977613A (es) |
AU (1) | AU2009227068A1 (es) |
BR (1) | BRPI0909189A2 (es) |
CA (1) | CA2717419A1 (es) |
ES (1) | ES2329327B1 (es) |
MX (1) | MX2010010094A (es) |
RU (1) | RU2010142456A (es) |
WO (1) | WO2009115634A1 (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010142827A1 (es) * | 2009-06-11 | 2010-12-16 | Proyecto De Biomedicina Cima, S. L. | Propiedades neuroprotectoras de 5'-metiltioadenosina |
WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
US20130096158A1 (en) * | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries, Ltd. | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Fingolimod |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
JP2014521658A (ja) * | 2011-07-28 | 2014-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
EP2609914A1 (en) * | 2011-12-29 | 2013-07-03 | Universitätsklinikum Hamburg-Eppendorf | Novel methods for treating or preventing neurodegeneration |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
UY34896A (es) * | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
CN104869983A (zh) * | 2012-12-21 | 2015-08-26 | 泰华制药工业有限公司 | 醋酸格拉替雷的透粘膜给药 |
CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0352609A1 (en) | 1988-07-29 | 1990-01-31 | BIORESEARCH S.p.A. | Use of adenosine derivatives in preparing pharmaceutical compositions possessing immunostimulant activity |
WO1998016184A2 (en) | 1996-10-16 | 1998-04-23 | Icn Pharmaceuticals, Inc. | Purine l-nucleosides, analogs and uses thereof |
WO1999041247A1 (en) * | 1998-02-13 | 1999-08-19 | Autoimmune, Inc. | TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES |
WO2005009333A2 (en) | 2003-07-31 | 2005-02-03 | Yeda Research And Development Co. Ltd. | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
WO2006097547A1 (es) | 2005-03-17 | 2006-09-21 | Proyecto De Biomedicina Cima S.L. | Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes |
-
2008
- 2008-03-19 ES ES200800806A patent/ES2329327B1/es not_active Withdrawn - After Issue
-
2009
- 2009-03-18 BR BRPI0909189A patent/BRPI0909189A2/pt not_active IP Right Cessation
- 2009-03-18 CA CA2717419A patent/CA2717419A1/en not_active Abandoned
- 2009-03-18 CN CN200980109743XA patent/CN101977613A/zh active Pending
- 2009-03-18 AU AU2009227068A patent/AU2009227068A1/en not_active Withdrawn
- 2009-03-18 JP JP2011500244A patent/JP2011515377A/ja not_active Withdrawn
- 2009-03-18 US US12/922,980 patent/US8236778B2/en not_active Expired - Fee Related
- 2009-03-18 RU RU2010142456/15A patent/RU2010142456A/ru not_active Application Discontinuation
- 2009-03-18 MX MX2010010094A patent/MX2010010094A/es active IP Right Grant
- 2009-03-18 EP EP09722096A patent/EP2281566A1/en not_active Withdrawn
- 2009-03-18 WO PCT/ES2009/070067 patent/WO2009115634A1/es active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0352609A1 (en) | 1988-07-29 | 1990-01-31 | BIORESEARCH S.p.A. | Use of adenosine derivatives in preparing pharmaceutical compositions possessing immunostimulant activity |
WO1998016184A2 (en) | 1996-10-16 | 1998-04-23 | Icn Pharmaceuticals, Inc. | Purine l-nucleosides, analogs and uses thereof |
WO1999041247A1 (en) * | 1998-02-13 | 1999-08-19 | Autoimmune, Inc. | TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES |
WO2005009333A2 (en) | 2003-07-31 | 2005-02-03 | Yeda Research And Development Co. Ltd. | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
WO2006097547A1 (es) | 2005-03-17 | 2006-09-21 | Proyecto De Biomedicina Cima S.L. | Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes |
Non-Patent Citations (15)
Title |
---|
BOGGILD, J NEUROL, vol. 253, no. 6, 2006, pages VI/45 - VI/51 |
COSTELLO ET AL., CURR OP NEUROLOGY, vol. 20, 2007, pages 281 - 285 |
HARTUNG ET AL., LANCET, vol. 360, 2002, pages 2018 - 2025 |
JACOBS ET AL., ANN NEUROL, vol. 39, 1996, pages 285 - 294 |
JOHNSON ET AL., NEUROLOGY, vol. 45, 1995, pages 1268 - 1276 |
LANCET, vol. 352, 1998, pages 1498 - 1504 |
MORENO ET AL., ANN.NEUROL., vol. 60, no. 3, September 2006 (2006-09-01), pages 323 - 334 |
NEUROLOGY, vol. 43, 1993, pages 655 - 661 |
POLMAN ET AL., N ENGL J MED, vol. 354, 2006, pages 899 - 910 |
RAMTAHAL ET AL., J NEUROL, vol. 253, 2006, pages 1160 - 1164 |
REID., J HUM HYPERTENS, vol. 9, no. 4, 1995, pages S19 - S23 |
SCHIENK F. ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 106, 1964, pages 95 - 100 |
SCHLENK F. ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 106, 1964, pages 95 - 100 |
TOEWS ET AL., PROC AM THORAC SOC, vol. 2, 2005, pages 282 - 289 |
WILLIAMS-ASHMAN ET AL., BIOCHEM PHARMACOL., vol. 31, 1982, pages 277 - 288 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010142827A1 (es) * | 2009-06-11 | 2010-12-16 | Proyecto De Biomedicina Cima, S. L. | Propiedades neuroprotectoras de 5'-metiltioadenosina |
WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
US20130096158A1 (en) * | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries, Ltd. | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Fingolimod |
US8889627B2 (en) * | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
Also Published As
Publication number | Publication date |
---|---|
MX2010010094A (es) | 2010-11-12 |
US20110015132A1 (en) | 2011-01-20 |
AU2009227068A1 (en) | 2009-09-24 |
EP2281566A1 (en) | 2011-02-09 |
ES2329327A1 (es) | 2009-11-24 |
BRPI0909189A2 (pt) | 2016-08-02 |
JP2011515377A (ja) | 2011-05-19 |
ES2329327B1 (es) | 2010-09-17 |
CN101977613A (zh) | 2011-02-16 |
CA2717419A1 (en) | 2009-09-24 |
US8236778B2 (en) | 2012-08-07 |
RU2010142456A (ru) | 2012-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2329327B1 (es) | Combinaciones sinergicas de 5'-metiltioadenosina. | |
ES2420404T3 (es) | Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple | |
ES2688925T3 (es) | Tratamiento antiviral | |
Angulo et al. | Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | |
EP1912640B1 (en) | Use of the hdac inhibitor panobinostat for the treatment of myeloma | |
US20090246172A1 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
ES2728405T3 (es) | Tratamiento de la infección por virus de hepatitis delta | |
JP2018531945A (ja) | 免疫系を刺激するためのペプチドの使用 | |
WO2010004060A1 (es) | Uso de la cilastatina para reducir la nefrotoxicidad de distintos compuestos | |
KR20220119616A (ko) | Tlr7 효현제를 이용하여 바이러스 감염을 치료하는 방법 | |
ES2242024T3 (es) | Uso de ciertas pirrolidonas sustituidas tales como piracetam en el tratamiento de enfermedades virales y otras enfermedades. | |
JP2010507572A (ja) | 併用療法 | |
ES2959603T3 (es) | Envase farmacéutico para terapia con estriol para el tratamiento de la esclerosis múltiple | |
US20190241660A1 (en) | Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer | |
ES2223183T3 (es) | Combinaciones antivirales de lamivudina y adefovir. | |
AU3466799A (en) | Use of l-glu-l-trp in the treatment of hiv infection | |
EP4337200A1 (en) | Treatment using an antiviral compound and nitazoxanide | |
US20210220300A1 (en) | Methods of treating disease with dichlorphenamide | |
CN114340631A (zh) | 用于降低患者的血清磷酸盐的组合 | |
JP2003055215A (ja) | 肝線維化抑制剤 | |
US8772248B2 (en) | Drug delivery system | |
US11752113B2 (en) | Polyamine transport inhibitors as antivirals | |
US20240285589A1 (en) | Treatment using an antiviral compound and nitazoxanide | |
AU2002366531B2 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
ZA200404013B (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980109743.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09722096 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2717419 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009227068 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/010094 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12922980 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011500244 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009227068 Country of ref document: AU Date of ref document: 20090318 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7007/DELNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009722096 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010142456 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0909189 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100917 |